26.67 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||25.98 x 2200|
|Ask||28.28 x 800|
|Day's Range||26.30 - 26.96|
|52 Week Range||23.58 - 37.95|
|Beta (3Y Monthly)||0.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 23, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.00|
Natus Medical Inc NASDAQ/NGS:BABYView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for BABY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BABY had net inflows of $1.50 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
PLEASANTON, Calif., May 17, 2019 -- Natus Medical Incorporated (NASDAQ: BABY) today announced that Drew Davies, Executive Vice President and Chief Financial Officer will.
Despite Healthy Stock Performance, Spotlight Remains on Poor Governance and Lavish Spending by CEO By John Jannarone Argo Group International Holdings looks set for a showdown next week with activist investor Voce Capital Management. The risk: Argo may be overly focused on winning a small battle at the expense of defeat in a bigger […]
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Natus Medical, Inc. (“Natus” or “the Company”) (NASDAQ: BABY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. GlassHouse Research published a report about Natus on February 6, 2019, entitled, “Throw the BABY (Natus Medical Inc.) Out with the Bathwater.” The report accused the Company of deceptive accounting practices.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Natus Medical, Inc. resulting from allegations that Natus may have issued materially misleading business information to the investing public.
GAAP loss per share changed to $0.89 from $0.74No change to non-GAAP earnings per share PLEASANTON, Calif., May 06, 2019 -- Natus Medical Incorporated (NASDAQ: BABY) (the.
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of December 31. In this […]
PLEASANTON, Calif. (AP) _ Natus Medical Inc. (BABY) on Thursday reported a loss of $24.8 million in its first quarter. On a per-share basis, the Pleasanton, California-based company said it had a loss of 74 cents. For the current quarter ending in July, Natus Medical expects its per-share earnings to range from 25 cents to 32 cents.
First quarter revenue of $114.8 millionFirst quarter GAAP loss per share of $0.74; non-GAAP earnings per share of $0.09 PLEASANTON, Calif., April 25, 2019 -- Natus Medical.
NEW YORK, NY / ACCESSWIRE / April 25, 2019 / Natus Medical Incorporated (NASDAQ: BABY ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 25, 2019 at 4:30 ...
Natus Medical (BABY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLEASANTON, Calif., April 11, 2019 -- Natus Medical Incorporated (NASDAQ: BABY), a leading provider of medical devices and services, today announced that the Company will.
PLEASANTON, Calif., April 08, 2019 -- Natus Medical Incorporated (NASDAQ: BABY), a leading provider of medical devices and services, today announced that the Company will.
Per Natus Medical (BABY), this deal is strategically aligned with its business as besides concentrating on its core products, this sell-off will lead to planned investment in the high-growth markets.
Natus Medical Incorporated (BABY) (the “Company” or “Natus”), a leading provider of medical devices and services, today announced that it has signed a definitive agreement to sell its wholly-owned subsidiary, Medix Medical Devices, SRL (“Medix”), in an employee led buyout. As part of this divestiture, Natus will sell the Medix line of products, including incubators, warmers and other Medix products. Under its new ownership, Medix will continue to distribute Medix products as well as the previously distributed line of Natus products and other third party products in Argentina and Venezuela. Medix will also provide ongoing customer service, sales and customer support, and warranty and repair services for the Medix line of products.
NEW YORK, March 29, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against Natus Medical Incorporated (NASDAQ: BABY). Our investigation concerns.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Natus Medical Incorporated .
Most biotech drugs focus on clearing plaques from brain cells, but restoring patients' sleep quality is also proving to be necessary.